Fig. 3

Correlation between SETD2 deleterious mutations, MSI, and HRD. A Differences in MSIsensor scores in patients with SETD2 deleterious mutations and non-deleterious mutations in the TCGA cohort across seven cancer types. B Odds ratios and 95% confidence intervals calculated by multivariate binary logistic regression comparing the risk of MSI-H (MSIsensor score ≥ 4) for patients with and without mutated genes in endometrial carcinoma, colorectal carcinoma, and stomach adenocarcinoma. C Differences in HRD scores in patients with SETD2 deleterious mutations and non-deleterious mutations in the TCGA cohort across seven cancer types